BMS, Repligen settle Orencia fight

Four companies, two disputed patents, two multimillion-dollar settlements.

Repligen and Bristol-Myers Squibb buried the hatchet over Orencia, the rheumatoid arthritis treatment that's been subject to a patent dispute between the two companies. Bristol-Myers will pay $5 million plus royalties on U.S. net sales of Orencia to settle the disagreement. Repligen expects its first years' receipts from BMS to be around $30 million.

Meanwhile, Depomed will get about $10 million in payments and royalties in settlement of a patent infringement case against Ivax Corp. and its parent company, Teva Pharmaceuticals. The drug in question was the diabetes treatment Glucophage XR.

- check out the Orencia agreement
- see the Depomed news in the San Jose Business Journal

Related Articles:
NICE snubs Orencia, picks 3 rivals. Report
Regulatory panel gives BMS' Orencia unanimous approval. Report

Suggested Articles

It’s final: England won’t be covering AZ’s quick-selling Tagrisso in previously untreated non-small cell lung cancer patients with EGFR mutatations.

Top J&J meds have managed to hang onto market share in the face of new generics and biosims, but the drugmaker expects the pain to continue in 2020.

Lonza’s search for a new CEO is expected to be wrapped up this year as the CDMO homes in on a list of veterans from outside the company.